De Novo Classification Requests: When Your Medical Device Has No Predicate

Your Device Is Novel. Now What?

You have built something genuinely new. It does not fit neatly into an existing FDA classification, and a thorough predicate search has turned up nothing close enough to support a 510(k). For many medical device founders, this moment triggers panic. It should not. What it should trigger is a serious, strategic conversation about the De Novo classification pathway.

De Novo is not a consolation prize for devices that could not find a predicate. It is a legitimate, well-defined regulatory route established under Section 513(f)(2) of the Federal Food, Drug, and Cosmetic Act, and for the right device, it is exactly the right tool. Understanding when and how to use it is what separates founders who move efficiently toward market clearance from those who spend years stuck in regulatory limbo.

What De Novo Actually Is -- and Is Not

The De Novo process allows FDA to classify a novel, low-to-moderate risk device as Class I or Class II when no legally marketed predicate exists. A successful De Novo request results in a new device classification, complete with a product code, classification regulation, and -- critically -- special controls that define the risk mitigation requirements for that device type. Once granted, the De Novo order itself becomes a predicate that future manufacturers can reference in their own 510(k) submissions.

This is not a PMA. You are not submitting clinical data to prove safety and effectiveness under a burden-of-proof standard reserved for Class III devices. But De Novo is also not a streamlined 510(k). The evidentiary expectations are more rigorous, the review timelines are longer, and the strategic preparation required is substantially more involved. Treating it casually is one of the most expensive mistakes a startup can make.

When De Novo Is the Right Pathway

There are two routes into De Novo under 21 CFR Part 860, Subpart D. The first is a direct De Novo request submitted without a prior 510(k). The second follows an FDA Not Substantially Equivalent (NSE) determination -- commonly called a 'refuse to file' or 'not se' decision -- on a 510(k) submission. FDA's guidance document, 'De Novo Classification Process (Evaluation of Automatic Class III Designation),' finalized in 2021, provides the authoritative procedural framework and is essential reading for any regulatory team preparing a submission.

De Novo is appropriate when all of the following are true:

• The device is novel with no legally marketed predicate under 21 CFR 807.92(a)(3)
• The device presents low-to-moderate risk such that general and special controls are sufficient to provide reasonable assurance of safety and effectiveness
• The intended use and technological characteristics are well-defined and can support a coherent special controls framework

If your device is high-risk or if general and special controls cannot mitigate the identified risks, De Novo is not available to you. PMA becomes the required pathway under Section 515 of the FD&C Act.

What Goes Into a De Novo Request

A well-constructed De Novo request is not simply a 510(k) with the predicate section removed. It requires a fundamentally different architecture. Your submission must include:

• Device description and intended use: Precise, unambiguous, and defensible under FDA scrutiny
• Risk-based classification rationale: A thorough demonstration that Class II is appropriate, supported by a risk analysis grounded in ISO 14971
• Proposed special controls: This is where most submissions succeed or fail. You must propose the specific controls -- performance testing, labeling requirements, postmarket surveillance, clinical data, or combinations thereof -- that mitigate each identified risk
• Performance testing data: Bench testing, biocompatibility per ISO 10993, software documentation under FDA's software guidance framework if applicable, and any clinical evidence necessary to support your special controls rationale
• Labeling: Compliant with 21 CFR Part 801 and aligned with your proposed intended use

FDA's current statutory review goal for De Novo requests is 150 days under MDUFA V commitments, though complex submissions often require additional information requests that extend that timeline. Building a realistic project plan from day one -- one that accounts for FDA interaction, potential Additional Information (AI) letters, and internal resource constraints -- is not optional. It is foundational.

The Strategic Value Most Companies Overlook

Beyond market access, a granted De Novo order creates durable competitive value. Your device becomes the predicate. Competitors who want to enter your space using 510(k) must now reference your classification order and demonstrate substantial equivalence to your device. You have, in effect, defined the regulatory standard for your device category. For investors, that is a significant differentiator worth communicating clearly in your fundraising narrative.

Common Pitfalls That Derail De Novo Submissions

• Proposing special controls that are too vague for FDA to enforce or verify
• Underestimating the clinical or performance data needed to support the proposed controls
• Submitting without a pre-submission (Q-Sub) meeting to align with FDA on the classification rationale before filing
• Conflating 'novel' with 'high-risk' and failing to build a credible Class II argument
• Inadequate software documentation for devices with software functions, particularly those subject to FDA's 2023 guidance on predetermined change control plans

Start With a Pre-Submission Meeting

If you take one piece of advice from this article, let it be this: request a Pre-Submission (Q-Sub) meeting with FDA before you prepare your De Novo package. Under 21 CFR Part 812 and FDA's Q-Sub guidance, you can get written FDA feedback on your proposed classification rationale, special controls framework, and testing requirements. This interaction does not guarantee outcomes, but it dramatically reduces the risk of avoidable deficiencies and can save months of rework.

At ADB Consulting and CRO Inc., we have guided medical device companies through De Novo strategy from initial pathway analysis through FDA response management. If your device is novel and you are trying to determine whether De Novo is the right move -- or how to build a submission that holds up -- we are here to help.

Book a free discovery call with Andre Butler and the ADB Consulting team at adbccro.com. Bring your device concept, your predicate search results, and your questions. We will give you a straight answer on where you stand and what it takes to move forward.